In the past 15 years, B cells have been rediscovered to be not merely bystanders but rather
active participants in autoimmune aetiology. This has been fuelled in part by the clinical …

Abstract B7-H3 (also known as CD276) is a newly found molecule of B7 family, which may
be a promising target for cancer treatment. B7-H3 protein was demonstrated to be …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …

Despite the continuing development of immunomodulatory agents and supportive care, the
prognosis associated with lupus nephritis (LN) has not improved substantially in the past …

Bispecific antibodies (bsAbs) bind two different epitopes on the same or different antigens.
Through this dual specificity for soluble or cell-surface antigens, bsAbs exert activities …

Therapeutic antibodies are the largest class of biotherapeutics and have been successful in
treating human diseases. However, the design and discovery of antibody drugs remains …

Approved therapies for tendon diseases have not yet changed the clinical practice of
symptomatic pain treatment and physiotherapy. This review article summarizes advances in …

Monoclonal antibodies (mAbs) have been used in the development of immunotherapies that
target a variety of diseases, such as cancer, autoimmune diseases, and even viral infections; …

Autoimmune diseases are characterized by the recognition of self‐antigens by the immune
system, which leads to inflammation and tissue damage. B cells are directly and indirectly …

The expanding therapeutic armamentarium available for inflammatory bowel disease (IBD)
as well as multiple compounds in clinical development inevitably raises questions as to their …